These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen. Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742 [TBL] [Abstract][Full Text] [Related]
8. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura. Sui J; Zheng L; Zheng XL Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210 [TBL] [Abstract][Full Text] [Related]
9. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity]. Kato S; Fujimura Y Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861 [TBL] [Abstract][Full Text] [Related]
10. Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura. Cataland SR; Wu HM Semin Hematol; 2011 Oct; 48(4):242-50. PubMed ID: 22000089 [TBL] [Abstract][Full Text] [Related]
11. ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Sakai K; Matsumoto M; De Waele L; Dekimpe C; Hamada E; Kubo M; Tersteeg C; De Meyer SF; Vanhoorelbeke K Blood Adv; 2023 Jan; 7(1):131-140. PubMed ID: 36306339 [TBL] [Abstract][Full Text] [Related]
12. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies. Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428 [TBL] [Abstract][Full Text] [Related]
13. HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Sakai K; Kuwana M; Tanaka H; Hosomichi K; Hasegawa A; Uyama H; Nishio K; Omae T; Hishizawa M; Matsui M; Iwato K; Okamoto A; Okuhiro K; Yamashita Y; Itoh M; Kumekawa H; Takezako N; Kawano N; Matsukawa T; Sano H; Ohshiro K; Hayashi K; Ueda Y; Mushino T; Ogawa Y; Yamada Y; Murata M; Matsumoto M Blood; 2020 Jun; 135(26):2413-2419. PubMed ID: 32253422 [TBL] [Abstract][Full Text] [Related]
14. Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management. Roose E; Veyradier A; Vanhoorelbeke K Curr Opin Hematol; 2020 Sep; 27(5):320-326. PubMed ID: 32740038 [TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura. Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267 [TBL] [Abstract][Full Text] [Related]
16. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. le Besnerais M; Veyradier A; Benhamou Y; Coppo P Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806 [No Abstract] [Full Text] [Related]
17. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
18. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy. Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340 [TBL] [Abstract][Full Text] [Related]
19. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies. Mazepa MA; Park YA; Raval JS Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275 [TBL] [Abstract][Full Text] [Related]